Published in Gastroenterology on May 07, 2015
Survey Study on Barrett's Esophagus Screening (SCREEN-BE) | NCT04408105
Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use. Clin Epigenetics (2016) 1.39
Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas. Oncotarget (2016) 0.79
Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus. Gut (2015) 0.78
A Meta-Analysis and Systematic Review on the Association between Human Papillomavirus (Types 16 and 18) Infection and Esophageal Cancer Worldwide. PLoS One (2016) 0.76
Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database. Onco Targets Ther (2016) 0.76
The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo. Oncotarget (2016) 0.76
Web-Based Immersive Virtual Patient Simulators: Positive Effect on Clinical Reasoning in Medical Education. J Med Internet Res (2015) 0.75
Smoking Exposure and Survival of Patients with Esophagus Cancer: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract (2016) 0.75
Evidence-Based Operative Details in Esophageal Cancer Treatment: Surgical Approach, Lymphadenectomy, Anastomosis. Viszeralmedizin (2015) 0.75
Factors Influencing Compliance to Radical Treatment of Middle Thoracic Esophageal Cancer: An Audit from a Regional Cancer Centre. Indian J Palliat Care (2016) 0.75
Esophageal Endoscopic Submucosal Dissection Assisted by an Overtube with a Traction Forceps: An Animal Study. Gastroenterol Res Pract (2016) 0.75
Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res (2016) 0.75
Clinicopathological features and prognosis of patients <45 years old with esophageal adenocarcinoma comparing to other age groups. J Thorac Dis (2016) 0.75
5-Azacytidine suppresses EC9706 cell proliferation and metastasis by upregulating the expression of SOX17 and CDH1. Int J Mol Med (2016) 0.75
First reports of esophageal adenocarcinoma with white globe appearance in Japanese and Caucasian patients. Endosc Int Open (2016) 0.75
A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma. PLoS One (2017) 0.75
Potential role of P2X7R in esophageal squamous cell carcinoma proliferation. Purinergic Signal (2017) 0.75
Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma. Br J Surg (2017) 0.75
Alteration of Esophageal Microbiome by Antibiotic Treatment Does Not Affect Incidence of Rat Esophageal Adenocarcinoma. Dig Dis Sci (2016) 0.75
Time trends of esophageal and gastric cancer mortality in China, 1991-2009: an age-period-cohort analysis. Sci Rep (2017) 0.75
Racial Disparity in Gastrointestinal Cancer Risk. Gastroenterology (2017) 0.75
Screening and Preventive Strategies in Esophagogastric Cancer. Surg Oncol Clin N Am (2017) 0.75
Is Clinical Research in Oesophageal Cancer in South Africa in Crisis? A Systematic Review. World J Surg (2016) 0.75
Hospital volume and surgical mortality in the United States. N Engl J Med (2002) 25.79
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med (2012) 15.43
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 10.17
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med (1996) 10.09
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med (1996) 9.85
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med (2002) 8.72
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet (2002) 8.46
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med (1992) 7.40
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol (2001) 6.07
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol (2011) 5.94
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol (2005) 5.40
Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg (2011) 4.80
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol (2009) 4.34
Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg (2003) 4.30
Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila) (2008) 3.97
Obesity: a challenge to esophagogastric junction integrity. Gastroenterology (2006) 3.72
Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol (2002) 3.41
Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology (1995) 3.28
Transhiatal esophagectomy: clinical experience and refinements. Ann Surg (1999) 3.24
Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol (2009) 3.04
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol (1997) 2.73
The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA (1995) 2.68
Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology (2000) 2.66
Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol (2009) 2.66
Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev (2010) 2.54
Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis (2000) 2.52
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (2011) 2.51
Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol (2009) 2.46
A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol (2008) 2.39
Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology (2002) 2.38
Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol (2010) 2.37
Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 2.28
Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut (2007) 2.28
Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg (2005) 2.28
Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol (2009) 2.28
Refining esophageal cancer staging. J Thorac Cardiovasc Surg (2003) 2.18
Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization. Clin Gastroenterol Hepatol (2014) 2.07
Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ (2003) 2.04
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg (2001) 1.93
Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology (2013) 1.92
Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer (2008) 1.85
Global incidence of oesophageal cancer by histological subtype in 2012. Gut (2014) 1.84
The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol (2012) 1.81
Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc (2010) 1.79
Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer (2008) 1.78
Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology (2013) 1.77
Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch (2005) 1.74
Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol (2009) 1.74
Hospital volume and operative mortality in the modern era. Ann Surg (2014) 1.73
Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol (2004) 1.72
Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer (2008) 1.69
Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol (2002) 1.68
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol (2008) 1.62
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst (2010) 1.60
Challenge model for Helicobacter pylori infection in human volunteers. Gut (2004) 1.57
Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology (2013) 1.57
Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.56
Leptin and the risk of Barrett's oesophagus. Gut (2008) 1.54
Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol (2008) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol (2008) 1.52
Mechanism of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy. Gut (2011) 1.51
Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol (2008) 1.47
Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut (2006) 1.45
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Association of adiponectin multimers with Barrett's oesophagus. Gut (2009) 1.43
Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc (2004) 1.40
Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol (2013) 1.33
Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol (2012) 1.30
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.29
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29
Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol (2013) 1.29
Initial experience with minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg (2006) 1.28
Bacterial biota in reflux esophagitis and Barrett's esophagus. World J Gastroenterol (2005) 1.24
Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg (2010) 1.24
Dietary fibre for the prevention of colorectal adenomas and carcinomas. Cochrane Database Syst Rev (2002) 1.20
A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology (2010) 1.19
Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. Cancer Epidemiol Biomarkers Prev (2010) 1.19
Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut (2011) 1.18
Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) (2010) 1.18
Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 1.17
Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther (2010) 1.16
Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett's esophagus. Clin Gastroenterol Hepatol (2012) 1.15
Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer (2013) 1.15
Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut (2011) 1.13
Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol (2014) 1.13
A prospective comparison of totally minimally invasive versus open Ivor Lewis esophagectomy. Dis Esophagus (2012) 1.12